HARP - Harpoon Therapeutics reports partial response from HPN424 early-stage study in prostate cancer

Harpoon Therapeutics ([[HARP]] +3.7%) has reported a confirmed partial response for its most advanced program, HPN424 in Phase 1/2a study for the treatment of metastatic castration-resistant prostate cancer.At the highest fixed dose tested to date, 160ng/kg, one patient out of 7 showed confirmed partial response with tumor lesion reduction of 43%, and 3 of 7 patients have had serum PSA declines from baseline, including one patient with a PSA reduction greater than 50%.HPN424 was generally well tolerated and cytokine-related adverse events have been manageable. Severe adverse events include cytokine release syndrome (10%), ALT increase (11%) and AST increase (11%).Presentation of Phase 1 data and initiation of an expansion cohort is planned for 1H of 2021. Interim data from this expansion cohort is anticipated by the end of 2021.Also, another candidate HPN536 in Phase 1/2a, showed that among the relapsed/refractory ovarian cancer patients, 8 of 12 (67%) patients demonstrated stability of target

For further details see:

Harpoon Therapeutics reports partial response from HPN424 early-stage study in prostate cancer